CV Therapeutics Aims High Through its Agreement with Menarini
By Sally Mardikian PhD
Pharma Deals Review: Vol 2008 Issue 100 (Table of Contents)
Published: 12 Sep-2008
DOI: 10.3833/pdr.v2008.i100.129 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
CV Therapeutics (CVT) has high hopes for its angina drug Ranexa® (ranolazine extended release) after signing over the drug’s commercialisation rights to the Menarini Group in exchange for an upfront fee, milestones and royalties...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS